Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson (NYSE:JNJ)

Core Insights - Johnson & Johnson is set to release its third-quarter earnings results on October 14, with analysts expecting earnings of $2.76 per share, an increase from $2.42 per share in the same period last year [1] - The company projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier [1] FDA Approval - The U.S. FDA has approved Johnson & Johnson's Simponi (golimumab) for children with moderately to severely active ulcerative colitis who weigh at least 15 kg [2] - Following the FDA approval, shares of Johnson & Johnson rose by 0.7% to close at $191.08 [2] Analyst Ratings and Price Targets - Goldman Sachs analyst Asad Haider maintained a Buy rating and raised the price target from $186 to $212 [5] - Citigroup analyst Joanne Wuensch also maintained a Buy rating, increasing the price target from $200 to $213 [5] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $175 to $198 [5] - Guggenheim analyst Vamil Divan upgraded the stock from Neutral to Buy, raising the price target from $167 to $206 [5] - JP Morgan analyst Michael Weinstein maintained a Neutral rating and increased the price target from $185 to $200 [5]